copd　素材.pptVIP

* * * * Safety Pop, Source table: 8.1.015 * * OSS Pop, Source figure: 8.3.003 * * * * * * * Source table 6.004 * * * * * * ITT Pop, Source figure: 7.4.004 * * * * Speaker’s Notes: SFC showed significant improvements in lung function superior to components and placebo * * 29 * * * * * * * * * * * * * * SFC statistically significantly better than placebo at 6-months (p=0.001) Adjusted mean change at 3 years SFC= -1.2, FP = -0.2, Sal = 1, Plac = 2.1 Therefore Steroid containing groups prevented expected decline over 3 years I want to build this slide starting with placebo, then salmeterol, then FP then SFC Also put in line for zero Move legend to upper right arranged vertically building with the plots Haven’t yet formed a view about the nos. at the bottom of the slide * * SFC statistically significantly better than placebo at 6-months (p=0.001) Adjusted mean change at 3 years SFC= -1.2, FP = -0.2, Sal = 1, Plac = 2.1 Therefore Steroid containing groups prevented expected decline over 3 years I want to build this slide starting with placebo, then salmeterol, then FP then SFC Also put in line for zero Move legend to upper right arranged vertically building with the plots Haven’t yet formed a view about the nos. at the bottom of the slide * * * * * * * * The highest mortality rates were observed in patients with severe COPD (FEV1 30% predicted) taking placebo, SALM and FP. However, there was no interaction by baseline FEV1 (p = 0.402), i.e. there was no evidence that there was a difference in treatment effect for the different FEV1 groupings. This study was not powered to look at treatment differences within FEV1 categories, but the same trend can be seen across all three FEV1 groups. * * The highest mortality rates were observed in patients with severe COPD (FEV1 30% predicted) taking placebo, SALM and FP. However, there was no interaction by baseline FEV1 (p = 0.402), i.e. there was no evidence that there was a difference in treatment effect for the diff